Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Buisson

Showing results (21-30 of 166) with videos related to

Pageof 17
Sort By:
Journal of Crohn'S & Colitis|April 5, 2012
Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel diseaseAbdenour Babouri, Anthony Buisson, Marc-André Bigard, et al.
European Journal of Gastroenterology & Hepatology|April 10, 2015
Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapyCédric Duron, Marion Goutte, Bruno Pereira, et al.
Therapeutic Advances in Gastroenterology|November 3, 2025
Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn's disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS studyGuillaume Le Cosquer, Bruno Pereira, Arthur Jammet, et al.
Intestinal Research|February 9, 2026
First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER studyDiari M'Baye, Marianne Hupé, Marie Dodel, et al.
Crohn'S & Colitis 360|March 6, 2026
Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practiceLucine Vuitton, Mathurin Fumery, Lucile Foulley, et al.
HIV Medicine|November 30, 2023
Impact of screening programme to prevent anal cancer in high-risk patients with HIVEloïse Leclerc, Christine Jacomet, Laurent Siproudhis, et al.
Therapeutic Advances in Gastroenterology|March 28, 2025
Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's diseasePauline Wils, Mathurin Fumery, Maria Nachury, et al.
World Journal of Gastroenterology|June 11, 2025
Direct comparison of simultaneous and sequential endoscopic metallic bilateral stenting in malignant hilar biliary obstructionThomas Guilmoteau, Olivier Rouquette, Anthony Buisson, et al.
Inflammatory Bowel Diseases|April 13, 2026
Frailty in inflammatory bowel disease: a missing link in personalized care for the aging IBD populationGuillaume Le Cosquer, Cyrielle Gilletta, Bharati Kochar, et al.
The American Journal of Gastroenterology|April 7, 2025
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel DiseasesYannick Hoffert, Zhigang Wang, Mathurin Fumery, et al.
Pageof 17

Showing results (21-30 of 166) with videos related to

Sort By:
Pageof 17
Journal of Crohn'S & Colitis|April 5, 2012
Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel diseaseAbdenour Babouri, Anthony Buisson, Marc-André Bigard, et al.
European Journal of Gastroenterology & Hepatology|April 10, 2015
Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapyCédric Duron, Marion Goutte, Bruno Pereira, et al.
Therapeutic Advances in Gastroenterology|November 3, 2025
Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn's disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS studyGuillaume Le Cosquer, Bruno Pereira, Arthur Jammet, et al.
Intestinal Research|February 9, 2026
First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER studyDiari M'Baye, Marianne Hupé, Marie Dodel, et al.
Crohn'S & Colitis 360|March 6, 2026
Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practiceLucine Vuitton, Mathurin Fumery, Lucile Foulley, et al.
HIV Medicine|November 30, 2023
Impact of screening programme to prevent anal cancer in high-risk patients with HIVEloïse Leclerc, Christine Jacomet, Laurent Siproudhis, et al.
Therapeutic Advances in Gastroenterology|March 28, 2025
Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's diseasePauline Wils, Mathurin Fumery, Maria Nachury, et al.
World Journal of Gastroenterology|June 11, 2025
Direct comparison of simultaneous and sequential endoscopic metallic bilateral stenting in malignant hilar biliary obstructionThomas Guilmoteau, Olivier Rouquette, Anthony Buisson, et al.
Inflammatory Bowel Diseases|April 13, 2026
Frailty in inflammatory bowel disease: a missing link in personalized care for the aging IBD populationGuillaume Le Cosquer, Cyrielle Gilletta, Bharati Kochar, et al.
The American Journal of Gastroenterology|April 7, 2025
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel DiseasesYannick Hoffert, Zhigang Wang, Mathurin Fumery, et al.
Pageof 17